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ABSTRACT 
Antibody exerts various immune responses via binding to Fc receptors 
expressed on immune cells. Although several reports have demonstrated that IgM 
prevents autoantibody production, the role of IgM Fc receptors is largely unknown. To 
analyze the involvement of FcR (CD351), an Fc receptor for IgM and IgA expressed 
on B cells and follicular dendritic cells (FDCs), in IgM-mediated suppression of 
autoantibody production, we generated mice deficient in FcR on the background of 
MRL/MpJ-Faslpr/lpr (Fcamr-/-Faslpr/lpr) mice. Fcamr-/-Faslpr/lpr mice showed significantly 
lower titers of IgG autoantibodies against double strand (ds) DNA, histone and 
cardiolipin in the sera than did Fcamr+/+Faslpr/lpr mice. Moreover, Fcamr-/-Faslpr/lpr mice 
showed higher survival rate at the ages of 28, 32 and 40 weeks old, compared with 
Fcamr+/+Faslpr/lpr mice. These results suggest that FcR enhances, rather than 
suppresses, autoantibody production.  
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1. Introduction 
After binding to an antigen, immunoglobulin (Ig) initiates various immune 
responses via binding to a certain receptor for the Fc portion, called Fc receptor (FcR) 
(Daeron, 1997; Ravetch, 1997). Extensive studies demonstrated that FcRs for IgG (FcRI, 
FcRIIb, FcRIII and FcRIV) and IgE (FcRI and FcRII) play pivotal roles in immune 
responses, such as inflammations, cytotoxicity and allergic reactions (Ravetch and 
Clynes, 1998; Takai, 2002). In contrast to the FcR and FcR, molecular and functional 
characteristics of Fc receptor for IgM remain incompletely understood. FcR (CD351) 
is an Fc receptor for IgM as well as IgA (Sakamoto et al., 2001; Shibuya et al., 2000). 
FcR forms an atypical dimer, for which the cytoplasmic region of FcR is required 
(Cho et al., 2010; Takagaki et al., 2013). FcR is moderately expressed on B cells and 
macrophages (Sakamoto et al., 2001; Shibuya et al., 2000), and most strongly on 
follicular dendritic cells (FDCs) (Cho et al., 2006; Honda et al., 2009; Usui et al., 2012), 
which is involved in germinal center (GC) formation (Chaplin and Zindl, 2006; Park and 
Choi, 2005). FcR-deficient mice showed increased GC formation and antibody 
production after immunization with T-independent (TI), but not T-dependent (TD), 
antigens (Honda et al., 2009). Thus, FcR negatively regulates humoral immune 
responses against TI antigens. 
IgM exists in the sera of naïve host as a natural antibody. IgM is also the first 
antibody to be produced by naive B cells upon antigen recognition. Thus, IgM may play 
an important role in the early phase of host defenses against variable bacterial and viral 
infections (Boes et al., 1998; Ochsenbein et al., 1999). In addition, IgM prevents 
autoantibody production (Boes, 2000; Carroll, 2004; Ehrenstein et al., 2000). Mice 
deficient in serum IgM showed increased anti-DNA IgG production, leading to 
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glomerulonephritis due to deposition of an immune complex with age (Ehrenstein et al., 
2000). Moreover, serum IgM deficiency in MRL/MpJ-Faslpr/lpr mice, which 
spontaneously develop an autoimmune disease that has many features resembling human 
systemic lupus erythematosus due to lymphoproliferation (lpr) mutation on the Fas gene, 
showed significantly increased serum IgG autoantibodies against dsDNA and histone, 
and shortened life span caused by severe glomerulonephritis, compared with 
MRL/MpJ-Faslpr/lpr mice with normal serum IgM (Boes et al., 2000). Thus, serum IgM 
prevents autoantibody production and ameliorates immunological disorders (Boes, 2000; 
Carroll, 2004; Ehrenstein et al., 2000). However, how IgM is involved in autoantibody 
production is largely unknown. 
Several reports have demonstrated that autoantibodies are produced in a T 
cell-independent manner (Groom et al., 2007; Herlands et al., 2008). Because FcR 
negatively regulates humoral immune responses against TI antigens (Honda et al., 2009), 
we hypothesized that IgM suppresses autoantibody production via interaction with 
FcR. To test this idea, we generated mice deficient in FcR on the background of 
MRL/MpJ-Faslpr/lpr  (Fcamr-/-Faslpr/lpr) mice, and investigated the role of FcR in 
IgM-mediated suppression of autoantibody production. 
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2. Materials and methods 
 
2.1 Mice 
Mice deficient in FcR on BALB/c background were previously described 
(Honda et al., 2009). The FcR-deficient mice were bred with MRL/MpJ-Faslpr/lpr 
(MRL/MpJ-Faslpr/JJmsSlc) mice purchased from Japan SLC, Inc. (Tokyo, Japan), and 
their offsprings were intercrossed to yield Fcamr+/+Faslpr/lpr and Fcamr-/-Faslpr/lpr mice. In 
all the experiment, we analyzed littermate mice to exclude the influence of the genetic 
backgrounds. Mice were maintained under specific pathogen free conditions. All 
experiments were performed according to the guidelines of the Animal Ethics Committee 
of the University of Tsukuba Animal Research Center. 
 
2.2 ELISA 
2.2.1 Antibody 
Horseradish peroxidase (HRP)-conjugated sheep anti-mouse IgG antibody (GE 
Healthcare, Little Chalfont, UK), goat anti-mouse IgG1, IgG2a, and IgG2b antibodies 
(Bethyl, Mongomery, TX, USA) and goat anti-mouse IgG3 antibody (Southern Biotech, 
Birmingham, AL, USA) were used as secondary antibodies for detection. 
 
2.2.2 Measurement of autoantibodies  
96-well ELISA plate (Maxi Soap, Nunc, Roskilde, Denmark) was coated either 
with purified double-strand DNA (dsDNA, Sigma, St. Louis, MO, USA) in PBS at 5 
g/ml or histone (Roche, Mannheim, Germany) or cardiolipin (Sigma, St. Louis, MO, 
USA) in carbonate buffer (pH9.6) at 10 g/ml. In the case of dsDNA, plate was 
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pre-coated with protamine sulfate from salmon (Wako, Osaka, Japan) diluted in PBS at 
10 g/ml. After blocking with 3 % FCS-containing PBS, serially diluted serum samples 
were added. HRP-conjugated antibodies specific for each IgG isotype were then applied, 
followed by ABTS substrate (KPL, Gaithersburg, MD, USA). Antibody titers were 
determined relative to those of pooled sera obtained from mice with lpr mutation at 8~32 
weeks old. 
 
2.3 Biochemical examination of renal function 
Sera were obtained from Fcamr+/+Faslpr/lpr and Fcamr-/-Faslpr/lpr mice at the ages 
of 30~33 weeks old and from BALB/c mice at the ages of 8~12 weeks old, and measured 
for creatinine and blood urea nitrogen concentrations by using clinical chemical analyzer 
(Fuji Dri-Chem 3500, Fujifilm, Japan). 
 
2.4 Statistical analyses 
For statistical analysis of autoantibody production, student’s  unpaired t-test was 
applied. For statistical analysis of mice, Gehan-Breslow-Wilcoxon test and log-rank 
Mantel Cox test were applied for analyses of indicated ages and total survival rate, 
respectively. 
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3. Results and discussion 
To analyze the involvement of FcR in autoantibody production, we 
generated Fcamr+/+Faslpr/lpr and Fcamr-/-Faslpr/lpr mice. We collected sera from the both 
mice at the ages of 12, 16 and 20 weeks old, and measured the titers of IgG autoantibodies 
against double strand DNA (dsDNA), histone and cardiolipin. Fcamr+/+Faslpr/lpr mice 
showed elevated the titer of total anti-dsDNA IgG, which was further increased with age 
(Fig. 1A). However, anti-dsDNA IgG titers of Fcamr-/-Faslpr/lpr mice were significantly 
lower than those of Fcamr+/+Faslpr/lpr mice at the ages of 16 and 20 weeks old (Fig. 1A). 
Among IgG isotypes, anti-dsDNA IgG1 and IgG2b of 20 weeks old Fcamr-/-Faslpr/lpr 
mice were significantly decreased, compared with those of Fcamr+/+Faslpr/lpr mice (Fig 
1A). Similarly, anti-histone and anti-cardiolipin IgG1 and IgG2a titers of 
Fcamr-/-Faslpr/lpr mice were also significantly lower than those of Fcamr+/+Faslpr/lpr mice 
at the ages of 16 and/or 20 weeks old (Fig 1B, C). Collectively, these results suggest that 
FcR enhanced, rather than suppressed, IgG autoantibodies production in mice on the 
MRL/MpJ-Faslpr/lpr background. Moreover, Fcamr+/+Faslpr/lpr mice showed significantly 
higher survival rate at the ages of 28, 32 and 40 weeks old, compared with 
Fcamr+/+Faslpr/lpr mice, although the survival at the age of 52 weeks were comparable 
between Fcamr+/+Faslpr/lpr and Fcamr-/-Faslpr/lpr mice (Fig. 2). We also measured serum 
creatinine and blood urea nitrogen (BUN) concentrations of Fcamr+/+Faslpr/lpr and 
Fcamr-/-Faslpr/lpr mice at the ages of 30~33 weeks old. We did not observe elevated 
creatinine and BUN in the sera compared with BALB/c mice, indicating that renal 
dysfunction was not severe in either Fcamr+/+Faslpr/lpr or Fcamr-/-Faslpr/lpr mice at those 
ages, although the development of autoantibody deposition and/or glomerulonephritis 
could not be excluded (Fig. 3).  
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Recently, a new IgM Fc receptor, designated FcR, was identified (Kubagawa et 
al., 2009; Shima et al., 2010). Ouchida et al. have reported that aged FcR-deficient mice 
showed increased serum levels of rheumatoid factor, anti-dsDNA and anti-nuclear 
antibodies (Ouchida et al., 2012). Thus, FcR, rather than FcR, might be involved in 
IgM-mediated suppression of autoantibody productions. 
As for the molecular mechanisms of FcR-mediated enhancement of 
autoantibody production, two possibilities can be considered. First, since FcR 
expressed on B cells mediates internalization of IgM-coated antigen (Shibuya et al., 
2000), FcR may also internalize IgM immune-complex (IC) with dsDNA containing 
hypomethylated CpG DNA, resulting in TLR9 stimulation for anti-dsDNA IgG 
autoantibody production. Supporting this idea, evidences demonstrated that, despite 
relatively low abundance, hypomethylated CpG motif was included in mammalian DNA 
(Viglianti et al., 2003). Moreover, TLR9 activates autoreactive B cells, resulting in 
autoantibody production (Christensen et al., 2005; Leadbetter et al., 2002; Peng, 2005; 
Viglianti et al., 2003). Second, recent reports demonstrated that FDCs internalize and 
retain IC, and then recycle them back to the cell surface periodically (Heesters et al., 
2013). Prolonged retention of self-antigens on FDCs leads to autoantibody production 
(Kranich et al., 2010). Since FcR is strongly expressed on FDCs (Honda et al., 2009), 
FcR on FDCs may mediate internalization of IC of self-antigens with IgM 
autoantibody and prolong self-antigens retention on FDCs, leading to expansion of 
self-reactive B cells. Further studies should be required to clarify whether and how 
FcR and FcR is involved in autoantibody production.   
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Figure legends 
 
Fig. 1.  Autoantibody titers in the sera of Fcamr+/+Faslpr/lpr (WT) and Fcamr-/-Faslpr/lpr 
(KO) mice. Titers of anti-dsDNA (A), anti-histon (B) and anti-cardiolipin (C) antibodies 
of indicated IgG isotypes in sera of 12 (WT, n=37 ; KO, n=37 ), 16 (WT, n=37 ; KO, 
n=37 ) and 20 (WT, n=35 ; KO, n=36 ) weeks old mice were measured by ELISA. Each 
dot represents individual mice. Error bars indicate SEM. *, P < 0.05; **, P < 0.01. 
 
Fig. 2.  Survival of Fcamr+/+Faslpr/lpr (WT, n=38) and Fcamr-/-Faslpr/lpr (KO, n=37) mice. 
*, P < 0.05; **, P < 0.01. 
 
Fig. 3.  Creatinine (CRE) (A) and blood urea nitrogen (BUN) (B) concentrations were 
measured in the sera of Fcamr+/+Faslpr/lpr (WT) (n=5) and Fcamr-/-Faslpr/lpr (KO) (n=3) 
mice at the ages of 30~33 weeks old, and BALB/c mice at the ages of 8~12 weeks old 
(n=3).  
 
WT KO WT KO WT KO
0
200
400
600
800
1000
*
**
Total IgG
12weeks 16weeks 20weeks
an
ti-
ds
D
N
A
 Ig
G
 ti
te
r
WT KO WT KO WT KO
0
200
400
600
800
1000
*
IgG1
12weeks 16weeks 20weeks
an
ti-
ds
D
N
A
 Ig
G
1 
tit
er
WT KO WT KO WT KO
0
200
400
600
800
1000
IgG2a
12weeks 16weeks 20weeks
an
ti-
ds
D
N
A
 Ig
G
2a
 ti
te
r
WT KO WT KO WT KO
0
200
400
600
800
1000
**
IgG2b
12weeks 16weeks 20weeks
an
ti-
ds
D
N
A
 Ig
G
2b
 ti
te
r
WT KO WT KO WT KO
0
200
400
600
800
1000
IgG3
12weeks 16weeks 20weeks
an
ti-
ds
D
N
A
 Ig
G
3 
tit
er
A B C
WT KO WT KO WT KO
0
200
400
600
800
1000
Total IgG
12weeks 16weeks 20weeks
an
ti-
hi
st
on
 Ig
G
 ti
te
r
WT KO WT KO WT KO
0
200
400
600
800
1000
IgG1
12weeks 16weeks 20weeks
*
*
an
ti-
hi
st
on
 Ig
G
1 
tit
er
WT KO WT KO WT KO
0
200
400
600
800
1000
IgG2a
12weeks 16weeks 20weeks
*
an
ti-
hi
st
on
 Ig
G
2a
 ti
te
r
WT KO WT KO WT KO
0
200
400
600
800
1000
IgG2b
12weeks 16weeks 20weeks
an
ti-
hi
st
on
 Ig
G
2b
 ti
te
r
WT KO WT KO WT KO
0
200
400
600
800
1000
IgG3
12weeks 16weeks 20weeks
an
ti-
hi
st
on
 Ig
G
3 
tit
er
WT KO WT KO WT KO
0
200
400
600
800
1000
Total IgG
12weeks 16weeks 20weeks
an
ti-
ca
rd
io
lip
in
 Ig
G
 ti
te
r
WT KO WT KO WT KO
0
200
400
600
800
1000
IgG1
12weeks 16weeks 20weeks
**
an
ti-
ca
rd
io
lip
in
 Ig
G
1 
tit
er
WT KO WT KO WT KO
0
200
400
600
800
1000
IgG2a
12weeks 16weeks 20weeks
*
an
ti-
ca
rd
io
lip
in
 Ig
G
2a
 ti
te
r
WT KO WT KO WT KO
0
200
400
600
800
1000
IgG2b
12weeks 16weeks 20weeks
*
*
an
ti-
ca
rd
io
lip
in
 Ig
G
2b
 ti
te
r
WT KO WT KO WT KO
0
200
400
600
800
1000
IgG3
12weeks 16weeks 20weeksa
nt
i-c
ar
di
ol
ip
in
 Ig
G
3 
tit
er
Figure 1
0 28 56 84 112 140 168 196 224 252 280 308 336 364 392
0
25
50
75
100
WT
KO
                                                                                 .0 4   8  12 16 20 24 28 32  36 40 44 48  52 56
*
*
*
*
weeks
su
rv
iv
al
 (%
)
Figure 2
CRE
BALB/c WT KO
0.0
0.1
0.2
0.3
m
g/
dl
BUN
BALB/c WT KO
0
10
20
30
40
50
60
m
g/
dl
A B
Figure 3
